IRWD – ironwood pharmaceuticals, inc. - class a (US:NASDAQ)
Stock Stats
News
5/1
07:44 am
irwd
Medium
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 [Yahoo! Finance]
5/1
07:30 am
irwd
Medium
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
4/25
04:01 pm
irwd
Medium
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
4/8
07:45 pm
irwd
Low
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ironwood Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
4/6
02:04 am
irwd
Low
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/15/2024
07:00 am
irwd
-4.9%
MISS
11/9/2023
07:00 am
irwd
3.1%
MISS
8/8/2023
07:00 am
irwd
-10.2%
MISS
5/4/2023
07:00 am
irwd
4.8%
BEAT
3/1
12:59 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
-0.2%
3/1
12:59 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
-0.2%
4/25
04:32 pm
irwd
Medium
Form ARS IRONWOOD PHARMACEUTICALS For: Dec 31
4/25
04:29 pm
irwd
Medium
Form DEFA14A IRONWOOD PHARMACEUTICALS
4/25
04:28 pm
irwd
Medium
Form DEF 14A IRONWOOD PHARMACEUTICALS For: Jun 18
3/19
04:06 pm
irwd
Medium
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 15 Filed by: DENNER ALEXANDER J
3/12
04:06 pm
irwd
Neutral
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 08 Filed by: Emany Sravan Kumar
Show more
Top News Gainers
5/16 Form SC 13D IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP 11.5%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
Top News Decliners
3/17 Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: Dreyfus Andrew -10.8%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3